Accelerating the future of liquid biopsies with digital PCR and next-generation sequencing
The term liquid biopsy in the context of oncology refers to the real-time monitoring of the dynamic alterations of a tumor through detection of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomes in blood or other fluid samples.
As a complementary, noninvasive option to traditional biopsies, liquid biopsies enable the discovery of highly specific and sensitive biomarkers and can be used for dynamic and timely monitoring of tumor progression. At Thermo Fisher Scientific we are committed to developing high-quality liquid biopsy assays utilizing both digital PCR (dPCR) and targeted next-generation sequencing (NGS) technologies to enable cancer driver identification, serial monitoring, and recurrence detection. Through the powerful combination of targeted NGS panels, which provide comprehensive detection of cancer-related mutations, and dPCR assays, which offer rapid monitoring of a targeted set of mutations, liquid biopsies may soon become the future standard in cancer management.
Poster: Orthogonal Verification of Oncomine cfDNA Data with Digital PCR Using TaqMan dPCR Liquid Biopsy Assays
The wide-angle view provided by NGS panels, combined with digital PCR’s zoomed-in precision detection of DNA provide a more complete picture of the cancer genome. Download our poster to see how Oncomine cell-free nucleic acid assays and TaqMan dPCR Liquid Biopsy assays can be used in a complementary manner for liquid biopsy analysis.
Explore liquid biopsy solutions for discovery, monitoring, and recurrence
Discover cancer driver mutations
Analyze cell-free nucleic acid (cfNA) from cell-free DNA and RNA to identify primary cancer driver and resistance mutations using Oncomine cell-free nucleic acid assays.
Monitoring response and resistance
Determine response and resistance by routinely monitoring cancer-driver and therapy-resistant mutations using TaqMan Liquid Biopsy dPCR Assays.
Discover new driver mutations at recurrence
Identify new cancer driver and resistance mutations related to recurrence using Oncomine cell-free nucleic acid assays.
Liquid biopsy solutions and workflows
We offer complete liquid biopsy solutions from sample preparation through data analysis and interpretation. Learn more about our sample preparation kits and NGS, dPCR, and real-time PCR-based liquid biopsy solutions below.
Cell-free nucleic acid extraction
Master mix for dPCR
NGS assays and instruments
dPCR assays and instruments
castPCR assays and instruments
Data analysis and reporting
NGS analysis and reporting software
dPCR analysis software
castPCR analysis software
For Research Use Only. Not for use in diagnostic procedures.